Total Price: $0.00
Contact Information
Recombinant Rat CD80/B7-1 Protein (His tag)
SKU: PDER100068-100
To better serve you, we would like to discuss your specific requirement.
Please Contact Us for a quote.
Recombinant Rat CD80/B7-1 Protein (His tag)
| SKU # | PDER100068 |
| Expression Host | E. coli |
Description
| Synonyms | Activation B7-1 antigen, B7, CD80, Cd28l, Ly-53, Ly53, MIC17, T-lymphocyte activation antigen CD80, TSA1 |
| Species | Rat |
| Expression Host | E.coli |
| Sequence | Gly 41-Ala 262 |
| Accession | G3V671 |
| Calculated Molecular Weight | 24.3 kDa |
| Observed Molecular Weight | 32 kDa |
| Tag | N-His |
| Bio-activity | Not validated for activity |
Properties
| Purity | > 95 % as determined by reducing SDS-PAGE. |
| Endotoxin | Please contact us for more information. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis |
Background
The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.